Author/Authors :
Jنhnisch، نويسنده , , Hanka and Wehner، نويسنده , , Rebekka and Tunger، نويسنده , , Antje and Kunze، نويسنده , , Anja and Oehrl، نويسنده , , Stephanie and Schنkel، نويسنده , , Knut and Rohayem، نويسنده , , Jacques and Bornhنuser، نويسنده , , Martin and Tonn، نويسنده , , Torsten and Bachmann، نويسنده , , Michael and Schmitz، نويسنده , , Marc، نويسنده ,
Abstract :
Imiquimod and resiquimod represent Toll-like receptor (TLR) 7 and 8 agonists, which emerged as attractive candidates for tumor therapy. To elucidate immune cells, which mainly contribute to TLR7/8-mediated antitumoral activity, we investigated the impact of imiquimod and resiquimod on native human 6-sulfo LacNAc (slan) dendritic cells (DCs). We found that both TLR7/8 agonists significantly improve the release of various proinflammatory cytokines by slanDCs and promote their tumor-directed cytotoxic activity. Furthermore, resiquimod efficiently augmented the ability of slanDCs to stimulate T cells and natural killer cells. These results indicate that imiquimod and resiquimod trigger various immunostimulatory properties of slanDCs, which may contribute to their antitumor effects.
Keywords :
immunotherapy , dendritic cells , Resiquimod , IMIQUIMOD , tumor immunology
